Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Company Overview - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell a bundled offering of Wegovy on its platform [2]. Legal Allegations - The class action lawsuit alleges that Hims & Hers and its executives made false or misleading statements and failed to disclose the risks associated with their practices, which jeopardized patient safety [2]. - Novo Nordisk terminated its partnership with Hims & Hers on June 23, 2025, citing deceptive promotion and selling of illegitimate versions of Wegovy [3]. Stock Impact - Following the announcement of the termination of the partnership, Hims & Hers' stock price fell by more than 34% [3]. Class Action Process - Investors who purchased Hims & Hers securities during the specified class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of all class members [4].
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HIMS